Back to Search Start Over

Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party

Authors :
Pavel Jindra
Depei Wu
Rama Al Hamed
Paolo Bernasconi
Manos Nikolousis
Michael Loschi
Arnon Nagler
Abdul Hamid Bazarbachi
Selim Corbacioglu
Montserrat Rovira
Virginie Gandemer
Mohamad Mohty
Matteo Pelosini
Hélène Labussière
Zinaida Peric
John A. Snowden
Wilfried Schroyens
Fabio Ciceri
Bipin N. Savani
Kazimierz Hałaburda
Nicolaas Schaap
Lucía López-Corral
Frédéric Baron
Xavier Poiré
Myriam Labopin
Enric Carreras
Blandine Guffroy
Sylvain Chantepie
Ali Bazarbachi
UCL - SSS/IREC/SLUC - Pôle St.-Luc
UCL - (SLuc) Centre du cancer
UCL - (SLuc) Service d'hématologie
Source :
Bone Marrow Transplantation, 56, 917-927, Bone Marrow Transplantation, 56, 4, pp. 917-927, Bone marrow transplantation, Vol. 56, no.4, p. 917-927 (2021), Bone marrow transplantation
Publication Year :
2020
Publisher :
Springer Science and Business Media LLC, 2020.

Abstract

Contains fulltext : 245127.pdf (Publisher’s version ) (Closed access) Allogeneic hematopoietic cell transplantation (alloHCT) is a complex, potentially fatal therapy featuring a myriad of complications. Triggering event(s) of such complications vary significantly, but often a so-called "multi-organ failure" (MOF) is reported as the leading cause of death. The identification of the exact trigger of MOF is critical towards early and disease-specific intervention to improve outcome. We examined data from 202 alloHCT patients reported to have died of MOF from the EBMT registry aiming to determine their exact cause of death focusing on veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) due to its life-threatening, often difficult to capture yet preventable nature. We identified a total of 70 patients (35%) for whom VOD/SOS could be considered as trigger for MOF and leading cause of death, among which 48 (69%) were previously undiagnosed. Multivariate analysis highlighted history of hepatic comorbidity or gentuzumab use and disease status beyond CR1 as the only significant factors predictive of VOD/SOS incidence (OR = 6.6; p = 0.001 and OR = 3.3; p = 0.004 respectively). VOD/SOS-related MOF was widely under-reported, accounting for 27% of deaths attributed to MOF of unknown origin without a previous VOD/SOS diagnosis. Our results suggest most missed cases developed late VOD/SOS beyond 21 days post-alloHCT, highlighting the importance of the newly revised EBMT criteria.

Details

ISSN :
14765365 and 02683369
Volume :
56
Database :
OpenAIRE
Journal :
Bone Marrow Transplantation
Accession number :
edsair.doi.dedup.....ee58855cc246300cc029ffeebd3319ba